<DOC>
	<DOCNO>NCT00006219</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . Dehydroepiandrosterone clarithromycin may effective prevent multiple myeloma . PURPOSE : Randomized phase II trial compare effectiveness dehydroepiandrosterone clarithromycin treat patient may high risk develop multiple myeloma .</brief_summary>
	<brief_title>Chemoprevention Therapy Treating Patients High Risk Developing Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether dehydroepiandrosterone ( DHEA ) clarithromycin cause significant reduction bone marrow plasmacytosis , serum and/or urine M protein Bence Jones protein , surrogate endpoint biomarkers patient monoclonal gammopathy undetermined borderline significance . - Determine whether difference interleukin-1-beta ( IL-1-beta ) expression IL-1-beta dependent biomarkers ( adhesion molecule expression serum interleukin-6 level ) useful surrogate endpoint biomarkers patient . - Determine whether difference ploidy , proliferative index , nuclear pleomorphism index , circulate monoclonal plasma cell , Th1/Th2 ratio , serum s-interleukin-6R ( SIL-6R ) level , interleukin-6 SIL-6R expression , plasma cell apoptosis assay useful surrogate endpoint biomarkers patient . - Determine effect treatment regimens quality life patient . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients stratify accord disease ( monoclonal gammopathy undetermined significance v monoclonal gammopathy borderline significance ) monoclonal protein abnormality ( IgG v IgA ) . Patients randomize 1 4 treatment arm . - Arm I : Patients receive oral dehydroepiandrosterone ( DHEA ) daily . - Arm II : Patients receive oral clarithromycin twice daily . - Arm III : Patients receive oral placebo daily . - Arm IV : Patients receive oral placebo twice daily . Treatment continue 6 month absence disease progression unacceptable toxicity . Quality life assess baseline , 6 month , 12 month , disease progression . Patients follow every 3 month 1 year every 6 month 1.5 year . PROJECTED ACCRUAL : A total 75 patient ( 25 per treatment arm I II 25 arm III IV ) accrue study within 2.5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : New prior diagnosis 1 following : Monoclonal gammopathy undetermined significance Bone marrow plasma cell less 10 % Monoclonal gammopathy borderline significance Bone marrow plasma cell 1030 % Serum IgG IgA least 1.5 g/dL Bone marrow plasmacytosis great 30 % No multiple myeloma , amyloidosis , Bcell neoplasm No evidence bone lesion Prostatespecific antigen le 4 ng/mL PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ( unless history Gilbert 's disease ) AST ALT great 1.5 time ULN ( unless history Gilbert 's disease ) Renal : Creatinine great 1.8 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease No prior thromboembolic event within past 5 year Other : No prostate cancer clinically significant benign prostatic hypertrophy No prior malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No malignancy suspect mammogram No hypersensitivity DHEA , clarithromycin , macrolide antibiotic ( e.g. , erythromycin ) No insulindependent diabetes Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier method contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : At least 30 day since prior DHEA steroid may affect M protein Radiotherapy : Not specify Surgery : Not specify Other : At least 30 day since prior clarithromycin At least 30 day since prior agent may affect M protein No concurrent cisapride , terfenadine , pimozide , astemizole , loratadine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>multiple myeloma</keyword>
</DOC>